Division of Nephrology, Department of Medicine, University of California San Francisco, San Francisco, California, USA; Division of Pediatric Nephrology, Department of Pediatrics, University of California San Francisco, San Francisco, California, USA; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
Department of Nephrology and Dialysis, Sant'Anna Hospital, ASST Lariana, Como, Italy.
Kidney Int. 2023 Oct;104(4):655-680. doi: 10.1016/j.kint.2023.05.009. Epub 2023 May 24.
Anemia is common in patients with chronic kidney disease and is associated with a high burden of morbidity and adverse clinical outcomes. In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) published a guideline for the diagnosis and management of anemia in chronic kidney disease. Since then, new data from studies assessing established and emerging therapies for the treatment of anemia and iron deficiency have become available. Beginning in 2019, KDIGO planned 2 Controversies Conferences to review the new evidence and its potential impact on the management of anemia in clinical practice. Here, we report on the second of these conferences held virtually in December 2021, which focused on a new class of agents-the hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs). This report provides a review of the consensus points and controversies from this second conference and highlights areas that warrant prioritization for future research.
贫血在慢性肾脏病患者中很常见，与较高的发病率和不良临床结局负担相关。2012 年，肾脏病：改善全球预后组织（KDIGO）发布了慢性肾脏病患者贫血诊断和管理的指南。此后，评估治疗贫血和缺铁的既定和新兴疗法的新数据已经可用。自 2019 年以来，KDIGO 计划举办 2 次争议会议，以审查新证据及其对临床实践中贫血管理的潜在影响。在这里，我们报告了于 2021 年 12 月在线举行的第二次会议，重点讨论了一类新的药物——缺氧诱导因子脯氨酰羟化酶抑制剂（HIF-PHIs）。本报告回顾了第二次会议的共识点和争议点，并强调了未来研究需要优先考虑的领域。
Zotero 插件